Boehringer Ingelheim signs collaboration agreement in schizophrenia with Danish biotech company

The German pharmaceutical company Boehringer Ingelheim has entered into a research collaboration in schizophrenia with biotech company, Saniona, based in Medicon Valley, Greater Copenhagen. Since 2011, Boehringer Ingelheim has also worked with Copenhagen-based Zealand Pharma to discover drugs for the treatment of diabetes and obesity.

Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, have entered into a research collaboration with the objective to discover and develop new compounds for the treatment of schizophrenia. More specifically, to identify compounds that can restore brain network activity in patients with schizophrenia.

Advancing new treatment for schizophrenia

The programme aligns with Boehringer Ingelheim’s drug discovery strategy for neuropsychiatric diseases, focusing on investigating dominant symptom domains and the underlying neurobiology across mental disorders such as schizophrenia, Alzheimer’s disease and depression.

"We are very pleased to be working with Saniona’s experienced scientific and management team and to build on their ion channel drug discovery platform. Working together and blending our joint expertise and capabilities, we have the potential to advance new treatment options for schizophrenia", says Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim.

Copenhagen collaboration about diabetes and obesity

It is not the first time Boehringer Ingelheim joins forces with a Danish biotech company based in Medicon Valley. Since 2011, Boehringer Ingelheim has worked with Zealand Pharma in two preclinical peptides projects aiming to develop drugs for the treatment of diabetes and obesity.

One project deals with dual glucagon, GLP-1 receptor agonists, another deal with a drug that targets a previous unspoken biological target regarding treatment of both diabetes and obesity.

Medicon Valley – Scandinavia’s life science cluster

Medicon Valley in Greater Copenhagen is one of Europe is leading life science clusters. Located in the heart of Scandinavia, Medicon Valley brings together 400 life science and R&D-based companies, top universities and hospitals.

Read more about Medicon Valley, the leading life science cluster in Scandinavia.

Want to know more about life sciences in Greater Copenhagen?

If you want to know more about Greater Copenhagen’s life science industry, Medicon Valley or business opportunities, please contact Ann-Sofie Andersson, Business Development Manager Life Science, via mobile phone +45 29 39 68 09 or email asa@copcap.com.